Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.
Seaport Therapeutics has raised $15.0M in total funding. The most recent round was Grant. The last funding was announced in March 2026.
Seaport Therapeutics's investors include General Atlantic, ARCH Venture Partners, Foresite Capital, Advanced Research Projects Agency for Health, T. Rowe Price.
Seaport Therapeutics is headquartered in Boston, United States.
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.
Seaport Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Seaport Therapeutics — Funding & Investors." VCBacked, March 3, 2026, https://www.vcbacked.co/company/seaport-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Seaport Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/seaport-therapeutics
{{cite web |title=Seaport Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/seaport-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated